Roble Belko & Company’s NovoCure NVCR Stock Holding History

Roble Belko & Company’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$1K	–	430
2024 Q4	$1K	Hold	20	–	–	﹤0.01%	347
2024 Q3	$0	Hold	20	–	–	﹤0.01%	378
2024 Q2	$0	Hold	20	–	–	﹤0.01%	359
2024 Q1	$0	Hold	20	–	–	﹤0.01%	344
2023 Q4	$0	Hold	20	–	–	﹤0.01%	338
2023 Q3	$0	Hold	20	–	–	﹤0.01%	311
2023 Q2	$1K	Hold	20	–	–	﹤0.01%	276
2023 Q1	$1K	Hold	20	–	–	﹤0.01%	280
2022 Q4	$1K	Hold	20	–	–	﹤0.01%	303
2022 Q3	$2K	Hold	20	–	–	﹤0.01%	289
2022 Q2	$1K	Sell	20 -7	-26%	-$527	﹤0.01%	302
2022 Q1	$2K	Sell	27 -47	-64%	-$3.46K	﹤0.01%	343
2021 Q4	$6K	Sell	74 -6	-8%	-$602	﹤0.01%	279
2021 Q3	$9K	Sell	80 -20	-20%	-$3.02K	﹤0.01%	247
2021 Q2	$22K	Buy	+100	New	+$19.5K	0.01%	207
2020 Q4	–	Sell	-100	Closed	-$11K	–	328
2020 Q3	$11K	Hold	100	–	–	﹤0.01%	234
2020 Q2	$6K	Hold	100	–	–	﹤0.01%	274
2020 Q1	$7K	Hold	100	–	–	﹤0.01%	271
2019 Q4	$8K	Hold	100	–	–	﹤0.01%	277
2019 Q3	$7K	Hold	100	–	–	﹤0.01%	276
2019 Q2	$6K	Hold	100	–	–	﹤0.01%	281
2019 Q1	$5K	Hold	100	–	–	﹤0.01%	264
2018 Q4	$3K	Hold	100	–	–	﹤0.01%	274
2018 Q3	$5K	Hold	100	–	–	﹤0.01%	269
2018 Q2	$3K	Hold	100	–	–	﹤0.01%	292
2018 Q1	$2K	Hold	100	–	–	﹤0.01%	309
2017 Q4	$2K	Hold	100	–	–	﹤0.01%	295
2017 Q3	$2K	Buy	+100	New	+$1.97K	﹤0.01%	264

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Roble Belko & Company's NVCR Position: Q1 2025 in Review

Roble Belko & Company sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 20 shares — an estimated $1K sold.

Roble Belko & Company first reported a position in NVCR in Q3 2017 and held it in 28 quarters. The position peaked at $22K in Q2 2021. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

Roble Belko & Company reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
Roble Belko & Company sold 20 NovoCure shares in Q1 2025, an estimated $1K.
Roble Belko & Company first reported a position in NovoCure in Q3 2017 and held it in 28 quarters.
Roble Belko & Company's NovoCure position peaked at $22K in Q2 2021.
227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Roble Belko & Company's 13F filing for Q1 2025, filed 8 May 2025.